Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F. Seymour, Andrew W. Roberts, Jacqueline C. Barrientos et al.|The Lancet Oncology|2017Cited by 327
Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b StudyShuo Ma, Andrew W. Roberts, Danielle M. Brander et al.|Blood|2015Cited by 50